Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Audentes Therapeutics (BOLD) Stock Forecast & Price Target

Audentes Therapeutics logo
Get the Latest News and Ratings for BOLD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Audentes Therapeutics and its competitors.

Sign Up

BOLD Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$23.00$23.00$23.00N/A
Forecasted Upside748.71% Upside659.08% Upside514.97% UpsideN/A
Consensus Rating
Buy
Buy
Buy
N/A

BOLD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BOLD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Audentes Therapeutics Stock vs. The Competition

TypeAudentes TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside748.71% Upside27,212.41% Upside8.86% Upside
News Sentiment Rating
Neutral News

See Recent BOLD News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/22/2024Piper Sandler
2 of 5 stars
 Initiated CoverageOverweight$20.00+98.22%
4/22/2024Guggenheim
2 of 5 stars
 Initiated CoverageBuy$24.00+137.86%
4/22/2024Leerink Partners
1 of 5 stars
 Initiated CoverageOutperform$25.00+147.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:29 PM ET.


BOLD Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Audentes Therapeutics is $23.00, with a high forecast of $25.00 and a low forecast of $20.00.

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BOLD shares.

According to analysts, Audentes Therapeutics's stock has a predicted upside of 748.71% based on their 12-month stock forecasts.

Analysts like Audentes Therapeutics more than other "medical" companies. The consensus rating for Audentes Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BOLD compares to other companies.


This page (NASDAQ:BOLD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners